Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1968)	8/12/1997 10:06:00 PM
From: Pseudo Biologist	Respond to of 9719

Hi Richard, the answer to all your questions is yes -g- C2B8, C2B8+CHOP, Y2B8 (this would be the Yttrium conjugate that is already in clinical trials) and Bexxar, at least, will have to share the market. Bexxar (Coulter's murine anti-CD20 conjugated with I-131) is ahead of Y2B8 and behind C2B8 alone; not sure where it is in relation to C2B8+CHOP. The data of Bexxar aka B-1 therapy for phase I appeared in some detail in the J. Clinical Oncology in 1996 (one of the authors is Kaminski). They saw hints of efficacy even with the naked and imaging doses, as one would expect given that C2B8 works as well as it does. I think I have a table comparing (as far as one can do such) all 4 therapies, will post later if Vector does not do it first. And, thanks for the 5-point post; certainly food for thought. Max

To: scaram(o)uche who wrote (1968)	8/12/1997 11:16:00 PM
From: Andrew H	Respond to of 9719

Richard, PB gave you the short answer. I will give you the long one. If you are really interested, we have discussed the CLTR vs IDPH NHL issue at length. Most of these posts can be found between 1213-1328 on the VD thread. The discussion was almost entirely among PB, V1 and myself, so you wouldn't have to go through all of the posts. During the course of this conversation I was persuaded that the CLTR drug would indeed have a strong market for a number of reasons, although I did not believe this initially. So, check it out if you have the time and inclination.